Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Kronos Bio Inc
Healthcare
P/NCAV
0.44x
Ticker
KRON
Exchange
NASDAQ
Country
United States
Close
0.95 $
Mkt Cap
54.9M $
EV
-9.5M $
NCAV Burn Rate
35.7%
Current Ratio
7.24
Debt/Equity
0.0
EV/REV
-1.51x
EV/EBIT
0.1x
EV/FCF
0.1x
Dilution
1.7% p.A
Total Net Income
-508.2M $
Cheapness
99.0%
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average